Biomea Fusion Stock Today
| BMEA Stock | USD 2.84 0.50 14.97% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Biomea Fusion is trading at 2.84 as of the 26th of February 2025, a 14.97 percent decrease since the beginning of the trading day. The stock's open price was 3.34. Biomea Fusion has 45 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 27th of January 2025 and ending today, the 26th of February 2025. Click here to learn more.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. The company was incorporated in 2017 and is headquartered in Redwood City, California. The company has 36.24 M outstanding shares of which 10.73 M shares are currently shorted by private and institutional investors with about 14.87 trading days to cover. More on Biomea Fusion
Moving against Biomea Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Biomea Stock Highlights
Biomea Fusion (BMEA) is traded on NASDAQ Exchange in USA. It is located in 900 Middlefield Road, Redwood City, CA, United States, 94063 and employs 107 people. Biomea Fusion is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 102.92 M. Biomea Fusion conducts business under Biotechnology sector and is part of Health Care industry. The entity has 36.24 M outstanding shares of which 10.73 M shares are currently shorted by private and institutional investors with about 14.87 trading days to cover.
Biomea Fusion currently holds about 149.63 M in cash with (96.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.11, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Biomea Fusion Probability Of Bankruptcy
Ownership AllocationBiomea Fusion holds a total of 36.24 Million outstanding shares. Over half of Biomea Fusion's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Biomea Ownership Details
Biomea Fusion Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Biomea Fusion market risk premium is the additional return an investor will receive from holding Biomea Fusion long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.19) | |||
| Jensen Alpha | (1.39) | |||
| Total Risk Alpha | (1.36) | |||
| Treynor Ratio | (0.48) |
Biomea Stock Against Markets
Biomea Fusion Corporate Management
| Juan MD | Chief Officer | Profile | |
| Caroline Dupont | Senior Contracts | Profile | |
| Naomi Cretcher | Chief Officer | Profile | |
| Heow Tan | Chief Officer | Profile | |
| Stephan MD | Chief Officer | Profile | |
| Franco Valle | CFO Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomea Fusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Biomea Stock refer to our How to Trade Biomea Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomea Fusion. If investors know Biomea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomea Fusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biomea Fusion is measured differently than its book value, which is the value of Biomea that is recorded on the company's balance sheet. Investors also form their own opinion of Biomea Fusion's value that differs from its market value or its book value, called intrinsic value, which is Biomea Fusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomea Fusion's market value can be influenced by many factors that don't directly affect Biomea Fusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomea Fusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomea Fusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomea Fusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.